AR115288A1 - Anticuerpos humanizados contra el psma - Google Patents
Anticuerpos humanizados contra el psmaInfo
- Publication number
- AR115288A1 AR115288A1 ARP190102169A ARP190102169A AR115288A1 AR 115288 A1 AR115288 A1 AR 115288A1 AR P190102169 A ARP190102169 A AR P190102169A AR P190102169 A ARP190102169 A AR P190102169A AR 115288 A1 AR115288 A1 AR 115288A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- antibodies against
- humanized antibodies
- against psma
- fragments
- Prior art date
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title abstract 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title abstract 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 title 1
- 239000012634 fragment Substances 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente solicitud se refiere a anticuerpos humanizados y/o desinmunizados, a fragmentos de anticuerpos o a derivados de anticuerpos que se unen al antígeno de membrana específico de la próstata (PSMA) y a métodos para utilizar dichos anticuerpos, fragmentos de anticuerpos o derivados de anticuerpos, en el tratamiento del cáncer de próstata y de otras enfermedades neoplásicas así como neurológicas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18186591 | 2018-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115288A1 true AR115288A1 (es) | 2020-12-16 |
Family
ID=63259376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102169A AR115288A1 (es) | 2018-07-31 | 2019-07-31 | Anticuerpos humanizados contra el psma |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11976131B2 (es) |
| EP (1) | EP3830132B1 (es) |
| KR (1) | KR20210039389A (es) |
| CN (1) | CN112533956A (es) |
| AR (1) | AR115288A1 (es) |
| AU (1) | AU2019312801A1 (es) |
| BR (1) | BR112021001237A2 (es) |
| CA (1) | CA3104800A1 (es) |
| CL (1) | CL2021000146A1 (es) |
| CO (1) | CO2021000386A2 (es) |
| DK (1) | DK3830132T5 (es) |
| ES (1) | ES2934963T3 (es) |
| FI (1) | FI3830132T3 (es) |
| HR (1) | HRP20230115T1 (es) |
| HU (1) | HUE061078T2 (es) |
| IL (1) | IL279823A (es) |
| LT (1) | LT3830132T (es) |
| MX (1) | MX2021000783A (es) |
| PL (1) | PL3830132T3 (es) |
| PT (1) | PT3830132T (es) |
| RS (1) | RS63943B1 (es) |
| SG (1) | SG11202100607RA (es) |
| SI (1) | SI3830132T1 (es) |
| WO (1) | WO2020025564A1 (es) |
| ZA (1) | ZA202008095B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114010802A (zh) * | 2014-12-01 | 2022-02-08 | 宾夕法尼亚大学理事会 | Dna抗体构建体及其使用方法 |
| AU2020263959A1 (en) | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| IL302034A (en) | 2020-11-04 | 2023-06-01 | Heidelberg Pharma Res Gmbh | The composition includes a combination of an immune control inhibitor and a conjugated amatoxin antibody for use in cancer treatment |
| WO2023026235A1 (en) * | 2021-08-27 | 2023-03-02 | Janssen Biotech, Inc. | Anti-psma antibodies and uses thereof |
| AU2023251200A1 (en) | 2022-04-07 | 2024-10-03 | Heidelberg Pharma Research Gmbh | Methods of improving the therapeutic index of amatoxin-antibody conjugates |
| WO2024189048A1 (en) | 2023-03-13 | 2024-09-19 | Heidelberg Pharma Research Gmbh | Subcutaneously administered antibody-drug conjugates for use in cancer treatment |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0914155B1 (en) | 1996-03-25 | 2006-02-22 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen |
| US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
| DK1210374T3 (da) | 1999-07-29 | 2007-02-19 | Medarex Inc | Humane, monoklonale antistoffer over for prostataspecifikt membranantigen |
| US7666414B2 (en) * | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
| EP1726650A1 (en) * | 2005-05-27 | 2006-11-29 | Universitätsklinikum Freiburg | Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen |
| DE202007018529U1 (de) | 2007-07-07 | 2008-12-04 | Chamalow S.A. | Implantierbarer Funkfrequenzdefibrillator R.F. |
| EP4180458A1 (en) | 2008-10-01 | 2023-05-17 | Amgen Research (Munich) GmbH | Cross-species-specific psma x cd3 bispecific single chain antibody |
| TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| EP3587454A1 (en) * | 2018-06-27 | 2020-01-01 | Albert-Ludwigs-Universität Freiburg | Chimeric antigen receptors that bind to prostate specific membrane antigen |
-
2019
- 2019-07-30 RS RS20230088A patent/RS63943B1/sr unknown
- 2019-07-30 US US17/264,209 patent/US11976131B2/en active Active
- 2019-07-30 KR KR1020217003941A patent/KR20210039389A/ko unknown
- 2019-07-30 CA CA3104800A patent/CA3104800A1/en active Pending
- 2019-07-30 SG SG11202100607RA patent/SG11202100607RA/en unknown
- 2019-07-30 DK DK19745146.1T patent/DK3830132T5/da active
- 2019-07-30 HU HUE19745146A patent/HUE061078T2/hu unknown
- 2019-07-30 PL PL19745146.1T patent/PL3830132T3/pl unknown
- 2019-07-30 FI FIEP19745146.1T patent/FI3830132T3/fi active
- 2019-07-30 WO PCT/EP2019/070407 patent/WO2020025564A1/en active Application Filing
- 2019-07-30 ES ES19745146T patent/ES2934963T3/es active Active
- 2019-07-30 EP EP19745146.1A patent/EP3830132B1/en active Active
- 2019-07-30 LT LTEPPCT/EP2019/070407T patent/LT3830132T/lt unknown
- 2019-07-30 AU AU2019312801A patent/AU2019312801A1/en active Pending
- 2019-07-30 MX MX2021000783A patent/MX2021000783A/es unknown
- 2019-07-30 HR HRP20230115TT patent/HRP20230115T1/hr unknown
- 2019-07-30 PT PT197451461T patent/PT3830132T/pt unknown
- 2019-07-30 BR BR112021001237-0A patent/BR112021001237A2/pt unknown
- 2019-07-30 SI SI201930458T patent/SI3830132T1/sl unknown
- 2019-07-30 CN CN201980050808.1A patent/CN112533956A/zh active Pending
- 2019-07-31 AR ARP190102169A patent/AR115288A1/es unknown
-
2020
- 2020-12-22 ZA ZA2020/08095A patent/ZA202008095B/en unknown
- 2020-12-28 IL IL279823A patent/IL279823A/en unknown
-
2021
- 2021-01-18 CL CL2021000146A patent/CL2021000146A1/es unknown
- 2021-01-18 CO CONC2021/0000386A patent/CO2021000386A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021000386A2 (es) | 2021-07-19 |
| CL2021000146A1 (es) | 2021-07-30 |
| US20230250189A1 (en) | 2023-08-10 |
| DK3830132T3 (da) | 2023-01-02 |
| CA3104800A1 (en) | 2020-02-06 |
| LT3830132T (lt) | 2023-02-10 |
| CN112533956A (zh) | 2021-03-19 |
| SI3830132T1 (sl) | 2023-03-31 |
| WO2020025564A1 (en) | 2020-02-06 |
| HUE061078T2 (hu) | 2023-05-28 |
| DK3830132T5 (da) | 2024-08-19 |
| SG11202100607RA (en) | 2021-02-25 |
| PT3830132T (pt) | 2023-01-05 |
| EP3830132A1 (en) | 2021-06-09 |
| MX2021000783A (es) | 2021-03-31 |
| US11976131B2 (en) | 2024-05-07 |
| HRP20230115T1 (hr) | 2023-06-09 |
| RS63943B1 (sr) | 2023-02-28 |
| EP3830132B1 (en) | 2022-11-23 |
| JP2021532778A (ja) | 2021-12-02 |
| KR20210039389A (ko) | 2021-04-09 |
| AU2019312801A1 (en) | 2021-03-11 |
| ZA202008095B (en) | 2023-09-27 |
| ES2934963T3 (es) | 2023-02-28 |
| PL3830132T3 (pl) | 2023-04-17 |
| IL279823A (en) | 2021-03-01 |
| BR112021001237A2 (pt) | 2021-04-27 |
| FI3830132T3 (fi) | 2023-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR115288A1 (es) | Anticuerpos humanizados contra el psma | |
| PE20201341A1 (es) | Anticuerpos de union a gprc5d | |
| AR119295A1 (es) | Moléculas de unión a antígeno ligantes de cea | |
| AR107442A1 (es) | Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer | |
| CO2020013089A2 (es) | Anticuerpos contra mica y/o micb y sus usos | |
| CO2019001246A2 (es) | Anticuerpos anti-pd-1, un método de producción y un método para su uso | |
| PA8849001A1 (es) | Anticuerpos de c-met | |
| CO2021006869A2 (es) | Anticuerpos humanizados contra c-kit | |
| ECSP17011657A (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
| PE20171556A1 (es) | Agentes de union a cd123 y usos de estos | |
| EA201791554A1 (ru) | Биспецифичные антитела против cd3 и cd20 | |
| EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
| MX2020004573A (es) | Terapia de combinacion con agonistas de ox40 dirigidos. | |
| CU20150128A7 (es) | Conjugados fármaco-anticuerpo | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| BR112015027309A2 (pt) | anticorpo, composição, método de tratamento e uso de um anticorpo | |
| CO2021009693A2 (es) | Proteínas de unión a antígeno del receptor gamma anti-il2 | |
| CO2019007686A2 (es) | Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo | |
| AR114129A1 (es) | ANTICUERPOS TERAPÉUTICOS DIRIGIDOS CONTRA sPLA2-GIB Y SUS USOS | |
| BR112016024214A2 (pt) | anticorpos antigênicos anti-tf humanizados | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
| CL2019002735A1 (es) | Anticuerpos que se unen a steap-1. | |
| AR081321A1 (es) | N-cadherina: un blanco para el diagnostico y la terapia del cancer | |
| PH12020551968A1 (en) | Anti-sez6 antibody drug conjugates and methods of use |